We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

45 hedge funds and large institutions have $176M invested in Syndax Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more capital invested

Capital invested by funds: $102M → $176M (+$73.9M)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

4% less funds holding

Funds holding: 47 → 45 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
45
Holders Change
-2
Holders Change %
-4.26%
% of All Funds
1.2%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
18
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$11.5M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$3.88M
3
SFM
Sphera Funds Management
Israel
+$2.19M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.62M
5
TAM
Tiverton Asset Management
Delaware
+$1.51M

Top Sellers

1
RG
Redmile Group
California
-$2.47M
2
Jennison Associates
Jennison Associates
New York
-$2.02M
3
Norges Bank
Norges Bank
Norway
-$244K
4
BIT
BlackRock Institutional Trust
California
-$224K
5
Millennium Management
Millennium Management
New York
-$137K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
51
Catalyst Capital Advisors
New York
– -$2K -182 Closed
1 2
3

SNDX Hedge Fund Activity: Q3 2016 in Review

45 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2016, worth a combined $176M — up 73% from $102M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SNDX and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Wellington Management Group, adding an estimated $11.5M. The largest seller was Redmile Group, exiting entirely with an estimated $2.47M sold.

  • 45 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2016, down from 47 in Q2 2016.
  • Funds reported $176M of Syndax Pharmaceuticals stock for Q3 2016, up 73% quarter-over-quarter.
  • 4 funds opened new Syndax Pharmaceuticals positions in Q3 2016 and 6 closed out, a net change of -2 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2016 was Wellington Management Group, an estimated $11.5M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2016 was Redmile Group, an estimated $2.47M sold.

Based on aggregated 13F filings for Q3 2016.